



Form PTO-1449

INFORMATION DISCLOSURE STATEMENT

Atty. Docket:

469201-540

Serial No.:

09/848,377

Applicant: Leslie Johnson

Filing Date: May 3, 2001

Group: 1614 1648

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date
LO	A1 5,290,540	March 1, 1994	Prince et al.			
	B1					
	C1					
	D1					
	E1					

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub-Class	Translation
LO	F1 WO 01/82966	8 November 2001	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	G1					<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

LO	H1	Prince, G.A., "Respiratory Syncytial Virus Antiviral Agents", Expert Opinion on Therapeutic Patents, pages 753-762, 9/6 (1999).
	I1	Ottolini, M.G., et al., "Prevention and Treatment Recommendations for Respiratory Syncytial Virus Infection Background and Clinical Experience 40 years after Discovery," in Drugs, 54/6, pages 867-884, (1997).
	J1	Jiang, Zili, et al., "Autocrine Regulation and Experimental Modulation of Interleukin-6 Expression by Human Pulmonary Epithelial Cells Infected with Respiratory Syncytial Virus", Journal of Virology, Vol. 72, No. 3, March 1998, pages 2496-2499 (1998-03).
	K1	Prince, Gregory, et al., "Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in a Cotton Rat Model with Systemically Administered Monoclonal Antibody (Palivizumab) and Glucocorticosteroid", Journal of Infectious Diseases, Vol. 182, No. 5, November 2000 (2000-11), pages 1326-1330.
	L1	
	M1	
	N1	
	O1	
	P1	
	Q1	

Examiner:

Date Considered:

RECEIVED
OCT 02 2002
TECH CENTER 1600/2000
11 14 03 2002

EXAMINER: *LO* Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.